Toripalimab Combined With Definitive CCRT for LACC Patients

Launched by RUIJIN HOSPITAL · Feb 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a new treatment called toripalimab, combined with standard chemoradiotherapy (CCRT), for women with locally advanced cervical cancer. Cervical cancer is a serious health issue for many women, and while some early cases can be treated successfully, those with more advanced stages often have a harder time. The trial aims to see if adding toripalimab, an immunotherapy drug that helps the immune system fight cancer, can improve treatment outcomes for women who have not received any treatment before.

To be eligible for this trial, participants must be women over 18 years old who have recently been diagnosed with a specific type of cervical cancer called squamous cell carcinoma, at certain stages (IB3 to IVA), and have no signs of cancer spreading to other parts of the body. They should be in fairly good health and able to participate actively. Those who have had certain other treatments or health issues may not be eligible. Participants in this trial can expect to receive either the combination of toripalimab and CCRT or CCRT alone, while being closely monitored by the research team. This study could help provide important information on how to improve treatment for this challenging disease.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • more than 18 years old females
• • had newly diagnosed and previously untreated locally advanced squamous cell carcinoma of the uterine cervix
• • FIGO 2018 stage IB3 to IVA with no evidence of distant metastasis
• • ECOG PS 0-1 without major organ failure
• • signed informed consent voluntarily
• Exclusion Criteria:
• • previously suffered from immunodeficiency disorders
• • had any condition that researchers believed to be associated with increased risk of treatment
• • Previously received or currently receiving other PD-1 antibody treatments or other immunotherapies targeting PD-1/PD-L1